Replies to post #6613 on Amarin Corp Plc (AMRN)

[zoobuffdoc]

DRRC, Thank you for the info re Amarin. The issue remains: There is no reason, in my opinion for a longer-range bearish outlook. In the longer range, i.e. end of 2013 thru early 2014 I believe that the price will be substantially higher.
(1) Successes of Marine and Anchor trials.
(2) FDA approval of Marine and high likelihood of approval of Anchor in Dec.
(3) Reasonable if not exceptional launch and Rx growth to date. As Lovaza prescriptions expire and Anchor indication comes on line, growth will increase markedly. Reduce-it success (as predicted by JELIS) will propel it heavenward.
(4) No serious negative side effects. Lovaza has problems with increasing LDC and AF under certain circumstances.
(5) Patent protections for exclusivity (NCE really not essential, although would be useful psychologically)
(6) vASCEPA IS FAR MORE EFFECTIVE THAN "FISH OIL" AS CURRENTLY SOLD IN Costco OR WHEREVER. definitely not the "SNAKE OIL" of yore with salesmen selling all types of "tonics" etc. of little or no value - or harmful - as "cure-alls". Vascepa claims none of the "cure-alls" and limits claims to the well-founded and FDA recognized beneficial effects.
7. Not all medications are "prescription only" because of their inherent safety or dangerousness. Some are RX only because of the need to use them in a safe and effect5ive manner. That is, in cases of significant existing risk or of having risk of serious disease a person may require monitoring of physical condition and blood/imaging monitoring of the underlying organ system(s). This is called MEDICINE, not "quackery". This represents a goodly part of FDA application and approval. It is VERY expensive to prove such points, hence the reward for risk price of new prescription medications. It is NOT merely "price gouging". If we are to have new, effective medications coming from other than government, then how should testing for safety and effectiveness be paid for?
Bearish views at the moment are associated with trading strategies, NOT longer-term prospects. There is NO CASE for long-term bearish view. There is an excellent bullish case to be made.